Premium
Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6‐week, double‐blind, placebo‐controlled study
Author(s) -
Paleacu D.,
Barak Y.,
Mirecky I.,
Mazeh D.
Publication year - 2008
Publication title -
international journal of geriatric psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.28
H-Index - 129
eISSN - 1099-1166
pISSN - 0885-6230
DOI - 10.1002/gps.1892
Subject(s) - quetiapine , tolerability , placebo , dementia , clinical global impression , antipsychotic , atypical antipsychotic , psychiatry , clinical trial , psychology , medicine , psychosis , adverse effect , alzheimer's disease , disease , schizophrenia (object oriented programming) , pathology , alternative medicine
Setting Treating elderly patients with Alzheimer's disease (AD) and behavioral and psychological symptoms of dementia (BPSD) is challenging due to the increased risk of iatrogenic movement disorders with old neuroleptics and the seemingly increasing risk of cardiovascular events with newer atypical agents. Quetiapine is an atypical antipsychotic agent that warrants further investigation. Objectives To assess tolerability, safety, and clinical benefit of quetiapine in AD patients with BPSD. Participants and design AD patients with BPSD participated in a 6‐week randomized, double‐blind, placebo‐controlled trial. Quetiapine was increased on the basis of clinical response and tolerability. Primary efficacy assessments included the Neuropsychiatric Inventory (NPI) and Clinical Global Impression of Change (CGI‐C). Secondary efficacy measures included the Mini‐Mental State Examination (MMSE), the Simpson‐Angus Scale (SAS) and the Abnormal Involuntary Movement Scale (AIMS). Results Forty patients (26 women), mean age 82.2 (SD 6.4) years were enrolled, 27 completed treatment. Median dose of quetiapine was 200 mg/day. Significant NPI total scores reductions (79% for placebo and 68.5% for quetiapine) were observed. The CGI‐C score decreased significantly in the quetiapine group ( p = 0.009 at 6 weeks) and did not change significantly in the placebo group ( p = 0.48). The MMSE, AIMS, SAS scores and adverse events did not differ significantly between the two arms. Conclusions Quetiapine did not significantly improve psychosis scores. It did not cause cognitive and motor deterioration. These results might possibly be due to small sample size. Copyright © 2007 John Wiley & Sons, Ltd.